Mease, Philip J.
Hatemi, Gülen
Paris, Maria
Cheng, Sue
Maes, Peter
Zhang, Wendy
Shi, Rebecca
Flower, Andrea
Picard, Hernan
Stein Gold, Linda
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
https://doi.org/10.1016/s0140-6736(12)60642-4
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
https://doi.org/10.1007/s40257-023-00783-7
Documents that mention this clinical trial
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
https://doi.org/10.1016/s0140-6736(12)60642-4
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
https://doi.org/10.1007/s40257-023-00783-7
Documents that mention this clinical trial
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
https://doi.org/10.1016/s0140-6736(12)60642-4
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
https://doi.org/10.1007/s40257-023-00783-7
Documents that mention this clinical trial
AB0771 Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment in the liberate study
https://doi.org/10.1136/annrheumdis-2017-eular.5163
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
https://doi.org/10.1007/s40257-023-00783-7
Documents that mention this clinical trial
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
https://doi.org/10.1007/s40257-023-00783-7
Documents that mention this clinical trial
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
https://doi.org/10.1007/s40257-023-00783-7
Documents that mention this clinical trial
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
https://doi.org/10.1007/s40257-023-00783-7
Documents that mention this clinical trial
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
https://doi.org/10.1007/s40257-023-00783-7
Documents that mention this clinical trial
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
https://doi.org/10.1016/s0140-6736(12)60642-4
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies
https://doi.org/10.1136/rmdopen-2018-000669
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
https://doi.org/10.1007/s40257-023-00783-7
Documents that mention this clinical trial
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
https://doi.org/10.1016/s0140-6736(12)60642-4
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies
https://doi.org/10.1136/rmdopen-2018-000669
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
https://doi.org/10.1007/s40257-023-00783-7
Documents that mention this clinical trial
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
https://doi.org/10.1016/s0140-6736(12)60642-4
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies
https://doi.org/10.1136/rmdopen-2018-000669
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
https://doi.org/10.1007/s40257-023-00783-7
Documents that mention this clinical trial
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
https://doi.org/10.1016/s0140-6736(12)60642-4
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
https://doi.org/10.1007/s40257-023-00783-7
Documents that mention this clinical trial
Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE) (Results)
https://doi.org/10.1136/annrheumdis-2017-211568
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
https://doi.org/10.1007/s40257-023-00783-7
Documents that mention this clinical trial
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
https://doi.org/10.1007/s40257-023-00783-7
Documents that mention this clinical trial
Impact of apremilast on quality of life in Behçet’s syndrome: analysis of the phase 3 RELIEF study
https://doi.org/10.1136/rmdopen-2022-002235
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
https://doi.org/10.1007/s40257-023-00783-7
Funding for this research was provided by:
Amgen Inc.
Article History
Accepted: 4 April 2023
First Online: 14 June 2023
Declarations
:
: This study was sponsored by Amgen Inc.
: All studies included in this pooled analysis were conducted in accordance with the general ethical principles outlined in the Declaration of Helsinki and principles of Good Clinical Practice per the International Council for Harmonisation Guidelines and local regulations.
: Philip J. Mease: AbbVie, Amgen Inc., Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Sun, and UCB—grant/research support and consultant; Boehringer Ingelheim, GlaxoSmithKline—consultant; AbbVie, Amgen Inc., Eli Lilly, Janssen, Novartis, Pfizer, and UCB—speakers bureau. Gülen Hatemi: AbbVie, Amgen Inc., and Celgene Corporation—grant/research support; AbbVie, Boehringer Ingelheim, Novartis, and UCB Pharma—speaker. Maria Paris, Sue Cheng, Peter Maes, Wendy Zhang, Rebecca Shi, Andrea Flower, Hernan Picard: Amgen Inc.—employees and stockholders. Linda Stein Gold: AbbVie, Amgen, Arcutis, Celgene Corporation, Dermira, Dermavant, Eli Lilly, Galderma, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi Genzyme, UCB, and Valeant—honoraria, grants, and/or research funding as a speaker, investigator, and/or advisory board member.
: Studies received approval from an Institutional Review Board or Ethics Committee prior to commencement.
: Patients provided informed consent prior to study entry.
: Not applicable.
: Qualified researchers may request data from Amgen clinical studies. Complete details are available at ExternalRef removed.
: Not applicable.
: WZ, PM, and SC contributed to the study conception and design. Patient data collection was performed by PJM, LSG, and GH. Data analysis and interpretation were performed by HP, RS, AF, MP, and MC. All authors commented on previous versions of the manuscript, and all authors read and approved the final version of the manuscript.